MinervaX
Business Services · Denmark · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Nordre Fasanvej 215, Frederiksberg, Capi...Phone Number
+45 39178282Website
www.minervax.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MinervaX
MinervaX is a clinical stage biotech company dedicated to developing innovative vaccines, specifically targeting Group B Streptococcus. Their lead candidate, AlpN GBS, is designed for use in pregnant women and older adults to prevent adverse pregnancy outcomes and life-threatening infections. The company aims to address significant unmet medical needs and has raised nearly EUR 200M to support its clinical trials. MinervaX is supported by leading healthcare funds and boasts a team of experienced scientists and vaccine developers.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MinervaX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when MinervaX launches new products
Congratulate Masked Content for being promoted to Masked Content at MinervaX
Earning: See what the market has to say on MinervaX recently announced quarterly report
Funding: Get notified immidiatlly once MinervaX has new funding data
Check out if MinervaX is spiking on competitors!
MinervaX, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if MinervaX has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if MinervaX had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at MinervaX
Find 2 more new buyers
Company Profile Activity
Activity Insights
MinervaX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MinervaX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MinervaX.
MinervaX financials insights
Gather financial insights about MinervaX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$8.7M
2020
Series B
$57.6M
2022
Private Equity
$76.5M
2023
Other Financing Round
$56.7M
MinervaX Tech Stack
A closer look at the technologies used by MinervaX
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Executive Move
Executive Moves, Board of Directors
MinervaX News & Media
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX
COPENHAGEN, Denmark, Nov. 14, 2024 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of...MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply after regulatory approval Vaccine to address the unmet medical burden of GBS, both by maternal vaccination to...Denmark: Europe's hub for tech innovation and collaboration
Denmark's tech ecosystem thrives on innovation, collaboration, and sustainability. Centered in Copenhagen, it supports a diverse range of sectors including biotechnology, renewable energy, and digital...MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company's efforts to commence a Phase III clinical trial of its Maternal Vaccine...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MinervaX
Sign Up For FreeTo access detailed company insights
MinervaX is a clinical stage biotech company dedicated to developing innovative vaccines, specifically targeting Group B Streptococcus. Their lead candidate, AlpN GBS, is designed for use in pregnant women and older adults to prevent adverse pregnancy outcomes and life-threatening infections. The company aims to address significant unmet medical ne... Read More
